Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy.

Yurkovetskiy AV, Yin M, Bodyak N, Stevenson CA, Thomas JD, Hammond CE, Qin L, Zhu B, Gumerov DR, Ter-Ovanesyan E, Uttard A, Lowinger TB.

Cancer Res. 2015 Aug 15;75(16):3365-72. doi: 10.1158/0008-5472.CAN-15-0129. Epub 2015 Jun 25.

2.

Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.

Walsh MD, Hanna SK, Sen J, Rawal S, Cabral CB, Yurkovetskiy AV, Fram RJ, Lowinger TB, Zamboni WC.

Clin Cancer Res. 2012 May 1;18(9):2591-602. doi: 10.1158/1078-0432.CCR-11-1554. Epub 2012 Mar 5.

3.

XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer.

Yurkovetskiy AV, Fram RJ.

Adv Drug Deliv Rev. 2009 Nov 12;61(13):1193-202. doi: 10.1016/j.addr.2009.01.007. Epub 2009 Aug 12. Review.

PMID:
19682517
4.

Synthesis of a macromolecular camptothecin conjugate with dual phase drug release.

Yurkovetskiy AV, Hiller A, Syed S, Yin M, Lu XM, Fischman AJ, Papisov MI.

Mol Pharm. 2004 Sep-Oct;1(5):375-82.

5.

Persistent silver disinfectant for the environmental control of pathogenic bacteria.

Brady MJ, Lisay CM, Yurkovetskiy AV, Sawan SP.

Am J Infect Control. 2003 Jun;31(4):208-14.

PMID:
12806357

Supplemental Content

Loading ...
Support Center